drugset / Trial / NCT04715269

Role of Alprazolam in the Management of Acute Coronary Syndrome

NCT04715269

Phase 1/2 Unknown 48 enrolled Sohaib Ashraf
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. On one end due to the emergence of pharmaceutical technology, there is a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of this disease is increasing. Hence leading to up slopping trend in cardiovascular prevalence. Acute coronary syndrome is one of the most deadly and acute presentations of cardiology requiring immediate intervention to dampen the frequency of complications. One of the fundamental goals in the treatment of ACS is to lower the heart rate so that load on myocardial tissue can be reduced. In order to do so, we already have multiple options like beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood pressure unlike others).

Timeline

Start
2020-12-25
Primary completion
2021-11-15
Completion
2022-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule 0.5 mg